Latest news and press releases about Tenaya Therapeutics, Inc. (TNYA): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small mol...
Price
| Price | $0.66 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.05 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -108.05% |
| Return on Invested Capital | -136.78% |
| Return on Assets | -110.24% |
| Gross Margin | 263.67% |
| Operating Margin | -7929.89% |
| Net Margin | -7723.97% |
Related companies: ABEO · CRBU · ENTA · FHTX · HUMA · IMRX · NAUT
Explore sector: Healthcare · Biotechnology
More sections of TNYA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks